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All cytochromes P450s in the endoplasmic reticulum rely on P450 oxidoreductase (POR)
for their catalytic activities. Mutations in POR cause metabolic disorders of steroid
hormone biosynthesis and affect certain drug metabolizing P450 activities. We studied
mutations A115V, T142A, Q153R identified in the flavin mononucleotide (FMN) binding
domain of POR that interacts with partner proteins and P284L located in the hinge
region that is required for flexibility and domain movements in POR. Human wild-type
(WT) and mutant POR as well as CYP3A4 and CYP19A1 proteins in recombinant
form were expressed in bacteria, and purified proteins were reconstituted in liposomes
for enzyme kinetic assays. Quality of POR protein was checked by cytochrome c
reduction assay as well as flavin content measurements. We found that proteins carrying
mutations A115V, T142A located close to the FMN binding site had reduced flavin
content compared to WT POR and lost almost all activity to metabolize androstenedione
via CYP19A1 and showed reduced CYP3A4 activity. The variant P284L identified
from apparently normal subjects also had severe loss of both CYP19A1 and CYP3A4
activities, indicating this to be a potentially disease causing mutation. The mutation
Q153R initially identified in a patient with disordered steroidogenesis showed remarkably
increased activities of both CYP19A1 and CYP3A4 without any significant change in
flavin content, indicating improved protein–protein interactions between POR Q153R
and some P450 proteins. These results indicate that effects of mutations on activities of
individual cytochromes P450 can be variable and a detailed analysis of each variant with
different partner proteins is necessary to accurately determine the genotype-phenotype
correlations of POR variants.
Keywords: POR, P450 oxidoreductase, CYP19A1, CYP3A4, polymorphisms, protein–protein interaction,
cytochrome P450
INTRODUCTION
Cytochrome P450 proteins metabolize a wide range of drugs, steroids and xenobiotics
(Schuster and Bernhardt, 2007; Omura, 2010; Zanger and Schwab, 2013). There are two
distinct types of cytochrome P450 proteins in humans (Omura, 2010). Type 1 P450s, that are
located in the mitochondria, are primarily involved in the metabolism of steroids and use
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adrenodoxin/adrenodoxin reductase proteins as redox partners
(Omura, 2006; Zalewski et al., 2016). The type 2 P450s, located
in the endoplasmic reticulum, rely on a single redox partner,
the cytochrome P450 oxidoreductase (POR, NCBI# NP_000932,
UniProt# P16435), for supply of electrons (Lu et al., 1969). POR
is a flavoprotein that contains both the flavin mononucleotide
(FMN) and the flavin adenine dinucleotide (FAD) and supplies
electrons to cytochromes P450 and other proteins (Matsubara
et al., 1976; Nagao et al., 1983; Guengerich, 2005). The structure
of the FMN binding domain of human POR has been determined
by x-ray crystallography (Zhao et al., 1999) and a more recent
open conformation structure of POR shows potential interaction
possibilities for redox partners (Aigrain et al., 2009).
P450 oxidoreductase deficiency (PORD, OMIM: 613537 and
201750) is a form of congenital adrenal hyperplasia, initially
described in patients with altered steroidogenesis (Flück et al.,
2004) followed by several reports with a broad spectrum of
disorders (Adachi et al., 2004; Arlt et al., 2004; Pandey and Flück,
2013; Flück and Pandey, 2014; Pandey and Sproll, 2014; Burkhard
et al., 2017). Sequencing of the POR gene revealed mutations
in patients with disorders of steroid biosynthesis (Flück et al.,
2004; Miller et al., 2004; Pandey et al., 2004). Afterward, many
other laboratories reported mutations in POR in patients with
steroidogenic disorders and/or bone malformation syndromes
(Adachi et al., 2004; Arlt et al., 2004; Fukami et al., 2005;
Pandey and Flück, 2013; Riddick et al., 2013). While initial
studies on POR mutations focused on steroid metabolism,
effects on other partner proteins like heme oxygenase and drug
metabolizing P450s have also been studied (Agrawal et al.,
2008, 2010; Flück et al., 2010; Nicolo et al., 2010; Pandey
et al., 2010). Large scale sequencing projects have identified
many variations in the POR gene, in several different human
sub-populations, and multiple variants have been implicated in
altered drug metabolism (Gomes et al., 2008, 2009; Huang et al.,
2008; Agrawal et al., 2010; Nicolo et al., 2010; Pandey et al.,
2010). Since POR is involved in multiple steroid biosynthesis
reactions catalyzed by cytochrome P450 proteins, a complex
disorder of steroidogenesis is expected from mutations in POR
(Figure 1). Many POR variants found in patients as well as
normal population have been tested for enzymatic activities
(Adachi et al., 2004; Arlt et al., 2004; Fukami et al., 2005,
2006; Homma et al., 2006; Pandey, 2006; Huang et al., 2008;
Sim et al., 2009). While mutations in POR can be found in
all regions of the protein, based on analysis of previously
identified mutations, some general observations can be made.
Mutations found in the co-factor binding sites (FMN, FAD and
NADPH) generally result in a severe form of the disease with
the mutations causing loss of FMN or FAD showing most severe
effects on activities of all supported redox partners. We have
previously shown that aromatase (CYP19A1) activity responsible
for conversion of androgens to estrogens (Figure 1) is more
susceptible to changes in NADPH binding site mutations in
POR (Pandey et al., 2007; Flück et al., 2011; Flück and Pandey,
2017). The studies described in this report were conducted by
embedding POR and P450 proteins in liposomes followed by
removal of detergents. In the current study, we have investigated
effects of some mutations in the FMN binding domain and
the hinge region of POR that facilitate interactions with redox
partner proteins, including P450s, to transfer electrons from
NADPH.
MATERIALS AND METHODS
Recombinant Expression of POR and
Membrane Purification
The WT and variant POR (NCBI# NP_000932, Uniprot#
P16435) proteins were expressed in bacteria using the expression
constructs described previously (Huang et al., 2005, 2008; Pandey
et al., 2007; Nicolo et al., 2010). The protocol for expression
of N-27 form of POR variants and subsequent membrane
purification is described and adopted from our previous
publications (Huang et al., 2005; Pandey et al., 2007, 2010;
Parween et al., 2016; Flück and Pandey, 2017). The cDNAs for
WT or mutant POR in pET22b were transformed into Escherichia
coli BL21(DE3), single colonies were selected for growth on
ampicillin and grown in terrific broth pH 7.4 supplemented with
40 mM FeCl3, 4 mM ZnCl2, 2 mM CoCl2, 2 mM Na2MoO4,
2 mM CaCl2, 2 mM CuCl2, 2 mM H3BO3, 0.5 mg/ml riboflavin,
100 µg/ml carbenicillin at 37◦C to an optical density (OD)
600 nm of 0.6 and temperature was reduced to 25◦C for 16 h.
The bacterial cells were collected by centrifugation, washed with
PBS and suspended in 100 mM Tris–acetate (pH 7.6), 0.5 M
sucrose, and 1 mM EDTA and treated with lysozyme (0.5 mg/ml)
and EDTA (0.1 mM [pH 8.0]) at 4◦C for 1 h with slow stirring
to generate spheroplasts. The spheroplasts were pelleted by
centrifugation at 5000× g for 15 min; and suspended in 100 mM
potassium phosphate (pH 7.6), 6 mM MgOAc, 0.1 mM DTT,
20% (v/v) glycerol, 0.2 mM PMSF, and 0.1 mM DNase I; and
disrupted by sonication. A clear lysate devoid of cellular debris
was obtained by centrifugation at 12,000× g for 10 min, and then
the membranes were collected by centrifugation at 100,000 × g
for 60 min at 4◦C. Membranes were suspended in 50 mM
Potassium phosphate buffer (pH 7.8) and 20% (v/v) glycerol and
stored at−70◦C. Protein concentration was measured by RC-DC
protein assay (Protein Assay Dye Reagent, Bio-Rad, Hercules,
CA, United States) and POR content in membrane proteins was
quantitated by western blot analysis.
Quantification of POR Content in the
Bacterial Membranes by Western Blot
Analysis
For Western blots, 1 µg of WT and POR bacterial membrane
proteins were separated on SDS–PAGE gel and blotted on to
polyvinyldifluoride (PVDF) membranes. Blots were probed with
a rabbit polyclonal antibody against wild-type human POR
from Genscript (Genscript, Piscataway, NJ, United States) at a
dilution of 1:1000. We used a secondary goat anti-rabbit antibody
that was labeled with a phthalocyanine infrared dye (IRDye
700DX, LI-COR Bioscience Inc., Lincoln, NE, United States)
at a dilution of 1:10000. Signals were detected with the green
fluorescent channel (700 nm) on an Odyssey Infrared Imaging
System (LI-COR Bioscience Inc., Lincoln, NE, United States), and
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FIGURE 1 | Role of POR in the steroid hormone biosynthesis. In the first steps of steroid biosynthesis, cholesterol is transported to mitochondrion by steroidogenic
acute regulatory protein (StAR). Then, inside the mitochondria, the cholesterol is metabolized by CYP11A1 to pregnenolone, and adrenodoxin and adrenodoxin
reductase act as the redox mediators in this reaction. The pregnenolone produced in the mitochondria is further metabolized in the endoplasmic reticulum to
downstream products 17OHPreg, DHEA, androstenedione or androstenediol; and then this process continues toward the production of testosterone in the Leydig
cells of the testes. Testosterone is further metabolized to dihydrotestosterone (DHT) in the genital skin. In the placenta, DHEA is converted to androstenedione and
then to testosterone, which is further metabolized to estrogens. In fetal liver, inactive precursor DHEAS is converted to 16αDHEAS, which gets converted to
16αDHEA in placenta to produce estrogens. The estrogen biosynthesis process requires CYP19A1 activity that is dependent on POR. The deficiency in POR can
alter the enzymatic reactions of many cytochrome P450 enzymes and these changes can be variable based on structural properties of the mutation and nature of
the redox partner. CYP11A1, P450scc, cholesterol side-chain cleavage enzyme; StAR, steroidogenic acute regulatory protein; FDX1, Adrenodoxin; FDXR, NADPH
adrenodoxin oxidoreductase; CYP17A1, P450c17, 17α-hydroxylase/17,20-lyase; HSD3B2, 3βHSD2, 3β-hydroxysteroid dehydrogenase, type 2; CYB5, cytochrome
b5; POR, P450 oxidoreductase; HSD17B3, 17βHSD3, 17β-hydroxysteroid dehydrogenase, type 3. Full steroid names: 17OHPreg, 17-hydroxypregnenolone;
17OHProg, 17-hydroxyprogesterone; 17OH-DHP, 17-hydroxydihydroprogesterone (5α-pregnan-3α,17α-ol-20-one); DHEA, dehydroepiandrosterone. Copyright ©
2017 Udhane, Parween, Kagawa and Pandey.
bands were quantitated using Odyssey software. POR content of
each membrane preparation was measured, and all samples were
normalized against purified wild-type POR used as standard. In
all experiments the normalized amount of POR content was used
in each experiment for all mutants as well as WT protein.
Cytochrome c Reduction Assay by WT
and Mutant POR
The cytochrome c reduction by bacterially expressed WT or
mutant POR was assayed as described previously by measuring
the change in absorbance at 550 nm (ε = 21.1 cm−1 mM−1)
(Guengerich et al., 2009). Briefly, the reaction was performed
in 96-well plates, in triplicate, with 5 µg of POR membrane
preparation in each well, using a microplate reader (Spectramax
M2e, Molecular Devices, Sunnyvale, CA, United States). The
NADPH concentration was fixed at 100 µM and different
concentrations of cytochrome c (0.6–80 µM) were used. The
change in absorbance at 550 nm was monitored against time.
Data were fitted based on Michaelis–Menten kinetics (Michaelis
and Menten, 1913) using GraphPad Prism (GraphPad Software,
La Jolla, CA, United States) to determine the Vmax and Km.
Flavin Content Analysis of WT and
Mutant POR
To differentiate the conformational changes and effects of co-
factor binding, we evaluated the relative flavin content in POR
variants as the activity of POR is affected by the binding of
cofactors FMN and FAD. Protein bound flavin molecules were
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released by thermal denaturation of POR proteins (Faeder and
Siegel, 1973). Flavin content of WT and mutant POR proteins
(100 µg/ml) was determined by heating protein samples at 95◦C
for 10 min in the dark, followed by centrifugation at 14000 × g
for 10 min to remove the coagulated protein. The FMN and
FAD ratio was determined by measurement of fluorescence of the
supernatant at pH 7.7 and pH 2.6 (excitation at 450 nm, emission
at 535 nm) (Faeder and Siegel, 1973) using commercially
available FMN and FAD as standards (Sigma–Aldrich, Basel,
Switzerland).
CYP19A1 Expression and Purification
The CYP19A1 vector for bacterial expression was transformed
in E. coli BL21(DE3) cells and the recombinant protein
was expressed and purified following previously published
protocols (Kagawa et al., 2003; Kagawa, 2011), with slight
modifications. Briefly, a single transformed colony was selected
for protein expression at 25◦C. After 4 h of incubation, 1 mM
δ-aminolevulinic acid (a heme precursor) and 4 mg/ml arabinose
(for induction of molecular chaperones GroEL/GroES) were
added to the culture and further incubated for 20 h. Cells
were harvested and spheroplasts were prepared with 0.2 mg/ml
lysozyme in 50 mM Tris–Acetate (pH 7.6), 250 mM sucrose and
0.5 mM EDTA and stored at −80◦C. For protein purification,
spheroplasts were lysed using 10XCellLytic B (Sigma–Aldrich)
in buffer containing 100 mM potassium phosphate (pH 7.4),
500 mM sodium acetate, 0.1 mM EDTA, 0.1 mM DTT, 20%
glycerol, and 1 mM PMSF. The cell lysate was centrifuged
and the supernatants were pooled for purification by Ni2+
affinity chromatography. Purification was performed at 4◦C and
protein concentration after the dialysis was determined by DC
protein assay (Protein Assay Dye Reagent, Bio-Rad, Hercules,
CA, United States) using BSA as standard.
Aromatase Activity Measurement in
Reconstituted Liposome System
Purified recombinant CYP19A1 using the bacterial expression
system was used to test the effect of POR variants to support the
aromatase activity of CYP19A1. Standard tritiated water release
assay for the CYP19A1 activity was performed in a reconstituted
liposome system using androstenedione as substrate. Bacterial
membranes containing POR and purified CYP19A1 were
reconstituted into DLPC-DLPG liposomes. The liposomes were
prepared as described in Figure 2. Aromatase activity was
measured by the tritiated water release assay originally described
by Lephart and Simpson (1991) with modifications as described
by us previously (Pandey et al., 2007; Flück and Pandey,
2017) using a reconstituted lipid-CYP19A1-POR system and
androstenedione as the substrate. Reaction mixture consisted of
100 pmol of CYP19A1, 400 pmol of POR, 100 mM NaCl and 3H
labeled androstenedione ([1β-3H(N)]-andros-tene-3,17-dione;
∼20,000 cpm) in 100 mM potassium-phosphate buffer (pH 7.4).
Different concentrations (10–1000 nM) of androstenedione were
used for kinetic analysis. The catalytic reaction was initiated
by the addition of 1 mM NADPH and the reaction tube was
incubated for 1 h under shaking. Data were fitted based on
Michaelis–Menten kinetics using GraphPad Prism (GraphPad
Software, La Jolla, CA, United States).
CYP3A4 Activity Measurement in
Reconstituted Liposome System
To compare the activities of CYP19A1 with another steroid
binding cytochrome P450, we tested the effect of POR mutations
to support the enzyme activity of CYP3A4. The activity
of the major drug metabolizing enzyme CYP3A4 supported
by WT or mutant POR was tested using the fluorogenic
substrates [BOMCC (7-Benzyloxy-4-trifluoromethylcoumarin)
and DBOMF dibenzylmethylfluorescein] (Invitrogen Corp,
Carlsbad, CA, United States) as described earlier (Flück et al.,
2010). The purified CYP3A4 (CYPEX, Dundee, Scotland,
United Kingdom) was used to test the activities of the
POR variants using 20 µM BOMCC or 5 µM DBOMF as
substrate (the apparent Km value of CYP3A4 for BOMCC,
10 µM, DBOMF 2.5 µM were derived from pilot experiments
using WT POR and CYP3A4). In vitro CYP3A4 assays were
performed using a reconstituted liposome system consisting
of WT/mutant POR, CYP3A4 and cytochrome b5 at a ratio
of 4:1:1 (POR:CYP3A4:b5). Reconstitution of liposomes was
carried out similarly as described before. The final assay
mixture consisted of liposomes and proteins (80 pmol POR:
20 pmol CYP3A4: 20 pmol b5), 2.5 mM MgCl2, 2.5 µM
GSH and 20 µM BOMCC or 5 µM DBOMF in 50 mM
HEPES buffer and the reaction volume was 200 µl. The
catalytic reaction was initiated by addition of NADPH to
1 mM final concentration and fluorescence was monitored on
a Spectramax M2e plate reader (Molecular Devices, Sunnyvale,
CA, United States) at an excitation wavelength of 415 nm and
emission wavelength of 460 nm for BOMCC and at an excitation
wavelength of 490 nm and emission wavelength of 520 nm for
DBOMF.
Statistical Analysis
Data are presented as mean standard errors of mean (SEM)
in each group or replicates. Differences within the subsets of
experiments were analyzed using Student’s t-test with GraphPad
Prism (GraphPad Software Inc., CA, United States). P-values less
than 0.05 were considered statistically significant.
3D Protein Models
Three dimensional structural models of POR (NCBI#
NP_000932) proteins were obtained from protein structure
database1. We used the structures of the FMN binding domain
of human POR (PDB # 1B1C) as well as an open structure of
POR protein (PDB# 3FJO) to analyze the location of amino acids
described in this report (Zhao et al., 1999; Aigrain et al., 2009).
Structure models were drawn using the software Pymol2 and
rendering of images was performed with POVRAY3.
1www.rcsb.org
2www.pymol.org
3www.povray.org
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FIGURE 2 | Reconstitution of POR and CYP19A1 proteins into liposomes. Lipids (DLPC: DLPG) were dissolved in chloroform and kept overnight for drying in a fume
hood. Next day, dried lipids were solubilized in detergent to prepare liposomes. The CYP19A1 and POR membranes were added to the liposomes and the
protein-liposome mixture was incubated for 1 h with shaking to incorporate the proteins into the liposomes. After 1 h, biobeads were added to remove the
detergent, and samples were incubated for another 1 h. After incubation, the mixture was cleared by centrifugation and the supernatant was used for assay of
CYP19A1 activity. Copyright © 2017 Udhane, Parween, Kagawa and Pandey.
FIGURE 3 | Cytochrome c reduction assay with WT and mutant POR.
Cytochrome c reduction assays was performed with the WT and variant forms
of POR. Kinetic assay relied on the changes in absorbance at 550 nm when
oxidized cytochrome c is converted into reduced cytochrome c. Data were
fitted as Michaelis–Menten kinetics model using GraphPad Prism. The
calculated Km and Vmax values are summarized in Table 1.
RESULTS
Cytochrome c Reduction Assay
Cytochrome c reduction assay with WT and POR variants
was performed to assess the basic quality and general catalytic
efficiency of POR as well as internal electron transfer in POR.
As compared to WT POR, 40–70% loss of activity in reducing
cytochrome c was observed with POR variants A115V, T142A
and P284L (Figure 3 and Table 1). This loss of activity indicates
that these mutations affect electron transport in POR through
flavins to cytochrome c since reduction of cytochrome c requires
the participation of both FAD and FMN as do the cytochromes
P450. Interestingly, Q153R showed 25% higher cytochrome c
reduction activity than WT POR (Table 1).
Flavin Content
As compared to WT POR, a 40–50% decrease in flavin content
of A115V mutant was observed (0.52 mol FMN/mol of POR
and 0.59 mol FAD/mol of POR). Both the FMN as well as the
FAD binding was severely affected due to T142A mutation with
approximately 80% loss of relative flavin content as compared
to WT (0.19 mol FMN/mol of POR and 0.22 mol FAD/mol
of POR) (Figure 4). The total flavin content of the gain of
function mutation Q153R (1 mol FMN/mol of POR and 0.99 mol
FAD/mol of POR) was comparable to WT and for the loss
of function mutation P284L the FMN content was similar to
WT (0.91 mol FMN/mol of POR) while the FAD content was
reduced by 25% (0.75 mol FAD/mol of POR) suggesting that
these mutations do not severely affect either the FMN or the FAD
binding to POR (Figure 4).
CYP19A1-Aromatase Activity
The POR variants A115V, T142A and P284L showed almost
complete loss of CYP19A1 activity (Figure 5 and Table 1).
For the T142A variant, the apparent Km for androstenedione
was increased fourfold as compared to WT POR suggesting
that T142A mutation affects either substrate interaction of
CYP19A1 or the CYP19A1-POR interaction. The apparent Km
with P284L variant was comparable to that of WT POR but the
apparent Vmax was reduced by 85%. Interestingly, POR variant
Q153R showed 47% higher value of Vmax/Km compared to
WT POR.
CYP3A4 Enzyme Activity
The A115 V and T142A variants of POR showed 2–10%
activity compared to WT (Figure 6). In human POR residues
A115V and T142A are directly involved in FMN binding.
The POR variant P284L resulted in 12–15% of CYP3A4
activity (Figure 6). The CYP3A4 activity of POR variant
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TABLE 1 | Kinetic parameters for activities of cytochrome c reduction and CYP19A1 activity supported by WT and mutant POR.
Km, cytochrome c (µM) Vmax nmol/min/mg Vmax/Km % WT
Cytochrome c reduction assay
67.4 ± 11.2 1279 ± 123.7 19 100
A115V 20.9 ± 11.1∗ 133.4 ± 2.8∗ 6.4 34
T142A 27.0 ± 13.4∗ 298.1 ± 15.4∗ 11 58
Q153R 81.5 ± 18.2∗ 1968 ± 270.2∗ 24.2 127
P284L 53.7 ± 10.5∗ 610 ± 63.5∗ 11.4 60
Km androstenedione (nM) Vmax pmol/min/nmol Vmax/Km % WT
CYP19A1; aromatase (androstenedione to estrone)
WT 80 ± 14.5 0.72 ± 0.03 0.0090 100
A115V nd nd nd –
T142A 308.4 ± 121.5∗ 0.11 ± 0.01∗ 0.0004 5
Q153R 65.62 ± 11.38∗ 0.86 ± 0.03∗ 0.0132 147
P284L 82.4 ± 62.5∗ 0.039 ± 0.008∗ 0.0005 5
For the cytochrome c reduction assay, the NADPH concentration was fixed at 100 µM and different concentrations of cytochrome c (0.6–80 µM) were used. For the
conversion of androstenedione to estrone, variable concentrations (10–1000 nM) of androstenedione were used for kinetic analysis in presence of 1 mM NADPH. Data
are presented as mean ± SEM of independent replicates. ∗ Indicates p-values < 0.05. nd: not detectable.
FIGURE 4 | Flavin content of WT and mutant POR proteins. Flavin content was measured by boiling protein samples under different buffer conditions. Relative
fluorescence unit (RFU) of the flavins released from POR variants obtained at pH 7.7 (F7.7) and pH 2.6 (F2.6) were plotted. RFU of WT was set as hundred percent.
(A) Shows FMN measurements and (B) shows FAD measurements. p-values for significance analysis compared to wild-type sample are indicated above the bars.
Data are presented as mean ± SEM of three replicates.
Q153R was nearly three times more than wild-type (WT) POR
(Figure 6).
DISCUSSION
P450 oxidoreductase is a membrane associated protein that binds
NADPH, causing a conformation change that brings NADPH
and FAD close together to transfer electrons. Afterward, further
conformation changes cause a closing of the POR structure and
brings FAD and FMN closer for electron transfer from FAD to
FMN. The FMN binding domain of POR interacts with P450s
and other partner proteins through charge pair interactions
involving arginine and lysine residues on P450s and aspartate
and glutamate residues on POR. Considering the importance of
FMN binding domain of POR in protein–protein interactions we
investigated the effects of mutations in this region of POR for
enzymatic activities on partner proteins. The mutations studied
in this report are either located close to the FMN binding site
of POR (A115V, T142A and Q153R) or in the putative hinge
region (P284L) required for flexibility of POR to interact with
redox partners. Using WT and variant POR and P450 proteins
expressed in bacteria, we determined the enzymatic activities
for metabolism of androstenedione by CYP19A1 and compared
them with CYP3A4 activities which can bind and metabolize
testosterone. Some very interesting and surprising findings were
made from this study, including the severe effect of POR variant
A115V which was previously suspected as a polymorphism (rs
199634961, POR∗11) and shows variable activities (Huang et al.,
2005; Agrawal et al., 2008, 2010; Pandey et al., 2010; Pandey and
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FIGURE 5 | Aromatase activity supported by WT and mutant POR proteins.
Bacterially expressed purified recombinant CYP19A1 and POR membranes
were incorporated into liposomes and their activity to convert [3H] labeled
androstenedione to estrone was tested by the tritiated water release assay.
Data were fitted with Michaelis–Menten kinetics model using GraphPad Prism.
The calculated Km and Vmax values are summarized in Table 1.
Flück, 2013; Burkhard et al., 2017). The POR variants P284L was
found to result in severe loss of activities while mutation Q153R
showed an activating effect. These results provide further insights
into the interactions of POR with its redox partner proteins
and help in establishing the genotype-phenotype correlations of
POR variants and their metabolic effects. Loss of flavins could
explain differences in activities for some mutations. Since the
A115 and T142 residues are near the FMN binding site, a loss of
FMN binding could be expected. However, both these mutants
also showed loss of FAD binding indicating that binding of
FMN may influence FAD binding. A similar relationship of
FAD binding to FMN binding has been observed by Shen et al.
(1989) in experiments with rat POR. Several different proposals
could be made to explain this observation. It is likely that
binding of FMN is required for recognition of FAD by POR. An
FMN dependent change if affinity of POR for FAD is possible
(Shen et al., 1989). The observation of Kurzban and Strobel
(1986) that FAD comes of more readily from POR compared
to FMN seems to support the hypothesis that affinity of POR
for FMN is higher. Mutations in the FAD binding domain of
POR result in complete loss of activities (Flück et al., 2004;
Pandey et al., 2004; Huang et al., 2005; Pandey and Flück, 2013).
For some POR mutations a rescue of activities may be possible
by flavin supplementation (Marohnic et al., 2010; Nicolo et al.,
2010).
Aromatase catalyzes the conversion of androstenedione
to estrone (E1), testosterone to estradiol (E2) and
16-hydroxytestosterone to estriol (E3) (Simpson et al., 1994)
(Figure 1). The CYP19A1 reaction requires multiple interactions
with POR, and therefore, changes in redox partner binding
sites on either CYP19A1 or POR may alter enzymatic activities.
To test this hypothesis, we selected several mutations located
in the FMN binding domain and the hinge region of POR,
which facilitate interactions with partner proteins. One of
the variants studied here, the A115V was first identified in
a patient (Huang et al., 2005). The patient harboring A115V
FIGURE 6 | CYP3A4 activity supported by WT and mutant POR proteins.
CYP3A4 enzyme activity assays were performed to compare WT and mutant
POR using either (A) 20 µM BOMCC or (B) 5 µM DBOMF as substrate.
Activity with the WT POR was set as hundred percent and results are shown
as percentage of WT activity. Data are presented as mean ± SEM of three
independent replicates.
mutation was from Caucasian background and had Beare–
Stevenson syndrome, which results in skeletal as well as
genital abnormalities (Przylepa et al., 1996; Huang et al.,
2005). A rugated labia majora and anteriorly placed anus had
been reported but no steroid or biochemical analysis were
available (Huang et al., 2005). Structure analysis of A115V
mutation revealed hydrogen bonding interaction between A115
and V85 and Y87 residues located on the neighboring beta
sheet, implicating its role in structural stability (Figure 7A).
Previously Agrawal et al. (2008) have shown that A115V
mutation caused complete loss of CYP1A2 and CYP2C19
activities, while only a 20–30% loss of 17-hydroxylase and
17,20 lyase activities was observed in CYP17A1 assays (Huang
et al., 2005). Our results indicate the severe loss of CYP19A1
aromatization activity could lead to abnormal steroid metabolism
in patients with A115V mutation in POR gene. A detailed steroid
analysis of such patients would be necessary to confirm this
linkage.
The patient with T142A mutation was from Iraqi/Yemeni
parents and did not have bone malformation but showed
abnormal genitalia (Augarten et al., 1992). The ACTH
stimulation test for the adrenal function indicated combined
CYP17A1 and CYP21A2 deficiencies, but no genetic defects in
these genes were found. Augarten et al. (1992) had hypothesized
that a deficiency in another enzyme, likely a flavoprotein may
be the cause but this was not pursued further, and only in 2005
the T142A mutation in the POR from this patient was identified
(Huang et al., 2005). In previous reports a 97% loss of CYP1A2
activity and complete loss of CYP2C19 activity has been reported
by Agrawal et al. (2008) for the T142A mutation, while a 40–50%
loss of CYP17A1 activity was observed by Huang et al. (2005).
The patient with T142A mutation of POR had low serum levels of
testosterone; and androstenedione and dehydroepiandrosterone
sulfate were low (but present) and did not improve upon ACTH
stimulation, consistent with loss of CYP17A1 activities (Augarten
et al., 1992). This is consistent with crucial physiological role
of androgen regulating enzyme CYP17A1, where complete loss
of activities is lethal. The mutation T142A (POR∗12) is located
next to the Y143 residue which is crucial for the FMN binding
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FIGURE 7 | Location of amino acid changes in POR described in current study. The x-ray crystal structures of the human POR (NCBI# NP_000932) protein; the
FMN binding domain (PDB# 1B1C) and the flexible hinge region (PDB# 3FJO) showing the location of mutations studied in this report. (A) Location of residue A115.
Structure analysis revealed hydrogen bonding interaction between A115 and V85 and Y87 residues located on a neighboring beta sheet in the FMN binding domain
of POR, implicating its role in structural stability. The models are colored in rainbow colors with violet at the N-terminus and red at the C-terminus. The co-factors
FMN and FAD are shown as sticks. (B) Location of residues T142 and Q153. The mutation T142A is located next to Y143 residue crucial for FMN binding to POR
and its mutation affected FMN binding. The Q153 residue is located at the surface of POR and predicted to have a role in the interactions with the redox partners.
(C) A surface representation of the POR FMN binding domain showing mutated residues in red. The Q153 residue is exposed to surface, while residues A115 and
T142 are also partially exposed. (D) Location of P284 residue in the hinge region of the POR. Hinge region is required for conformational flexibility and mutations in
this region are predicted to cause conformational changes that would alter both the electron transport and the interaction with redox partners.
to POR, and its mutation may affect FMN binding (Figure 7B).
Consistent with this we found a severe loss of flavins in the
T142A variant of POR (Figure 4). Loss of flavins could also make
subtle conformation changes in POR and as these changes would
be in the FMN binding domain of POR which interacts with
redox partners via shape as well as charge-based protein–protein
interactions, a change in activities of redox partners is expected.
Severe loss of both CYP19A1 as well as CYP3A4 activities due to
T142A mutation indicates a major impact on both steroid and
drug metabolism in the patients carrying this mutation.
The mutation Q153R was first described from an
Algerian family and was the product of an abortion carried
out at 22 weeks of gestation due to information from an
ultrasonographic examination which showed craniosynostosis
with bilateral radiohumeral synostosis, bowing of long bones,
and arachnodactyly (Huang et al., 2005). The karyotype
of the fetus was 46,XY, and no abnormalities in external
genitalia were detected. Steroids were not measured, but,
since ABS was suspected, a GC-MS analysis of liver tissue
was performed which indicated “substantially increased”
lanosterol and dihydrolanosterol. In previous studies, the
Q153R (POR∗13) variant of POR was found to retain only
25–30% of WT activity in assays with CYP17A1 (Huang
et al., 2005) but has shown higher activities in other
assays (Agrawal et al., 2008). A higher level of activity
with CYP19A1 observed with this mutation would not
indicate any damaging effect on a 46,XY fetus, but GC-
MS analysis indicates this mutation may affect CYP51A1
activity. The Q153 residue is located at the surface of POR
and may have a direct role in the interactions with the redox
partners (Figure 7C). However, higher levels of activities
observed in both the CYP19A1, as well as the CYP3A4
assays indicate that the impact of Q153R variant may be
selective for individual P450 enzymes with some being
adversely affected while others would be activated due to
potentially better protein–protein interactions. The activating
effect of Q153R variant of POR can be useful for potential
biotechnological applications where commercial production of
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expensive chemicals through P450 mediated biotransformation is
the preferred method of manufacturing.
The last mutation studied in this report, the P284L (rs
72557938), is located in the hinge region of POR, that is
important for domain movements and efficient interactions
between FMN and FAD binding regions and for the transfer
of electrons from FAD to FMN (Figure 7D). In the sequencing
study by Huang et al. (2008) the P284L mutation was present
at an allele frequency of 0.003 in Chinese American population
and in the currently available ExAc dataset containing 121000
samples it is present at an allele frequency of 0.00004132. A 54%
loss of 17-hydroxylase activity was reported by Huang et al but
the 17,20 lyase activity of CYP17A1 was 82% of the WT POR
(Huang et al., 2008). No loss of flavin content was observed
in the P284L variant which indicates altered inter as well as
intra molecular protein–protein interactions may be responsible
for the loss of activities in both the CYP19A1 as well as the
CYP3A4 assays. Since the hinge region of POR is important
for the domain motions to bring the FMN closer to the FAD
for the transfer of electrons, a change in this region may
affect the efficiency of electron transport process in POR, and
therefore, affect the activities of partner proteins. It is possible
that some redox partners of POR may experience greater impact
on their catalytic activities while others may retain close to
WT activities depending on their mode of interaction with
POR.
In these studies, we have used POR and P450 proteins
embedded in liposomes and removed the detergents used for
solubilization of POR and P450s by treatment with biobeads
(Bio-Rad Corp., Hercules, CA, United States) which provided
a robust assay system. These results also emphasize the need
for assay of POR variants with different partner proteins and
substrates to accurately determine the impact of individual
variations. The major polymorphism observed in POR is A503V
(rs 1057868, POR∗28), which is present in about 27% of all
alleles and shows wide variability across different populations
(Caucasian and Hispanic populations: 31%; Pacific Islanders:
48%; Asian populations 35%; Japanese, 40%; African Americans
16%) (Burkhard et al., 2017). There is some evidence of
POR∗28 allele influencing the activities of drug metabolizing
enzymes but more direct evidence is needed before any firm
conclusions can be drawn (Pandey and Flück, 2013; Pandey
and Sproll, 2014). As seen with the P284L mutation, there
may be variations of POR in apparently normal populations
with potentially disease causing effects. Since POR variations
have now been linked to the metabolism of several drugs
and steroids, it may be prudent to include the sequencing of
POR gene while looking for genetic causes of altered drug or
steroid metabolism. A detailed examination of the polymorphic
variants of POR would be required to estimate their damaging
effects.
AUTHOR CONTRIBUTIONS
Participated in research design: SU, SP, and AP. Conducted
experiments: SU and SP. Contributed new reagents or analytical
tools: NK. Performed data analysis: SU, SP, and AP. Overall
supervision of the project: AP. Wrote or contributed the writing
of the manuscript: SU, SP, NK, and AP.
FUNDING
This research was funded by grants to AP by the Swiss National
Science Foundation (31003A-134926) and Bern University
Research Foundation and Department of Clinical Research,
University of Bern.
ACKNOWLEDGMENT
We thank Prof. Walter L. Miller (UCSF, San Francisco, CA,
United States) for providing several POR expression constructs.
REFERENCES
Adachi, M., Tachibana, K., Asakura, Y., Yamamoto, T., Hanaki, K., and
Oka, A. (2004). Compound heterozygous mutations of cytochrome P450
oxidoreductase gene (POR) in two patients with Antley-Bixler syndrome. Am.
J. Med. Genet. A 128A, 333–339. doi: 10.1002/ajmg.a.30169
Agrawal, V., Choi, J. H., Giacomini, K. M., and Miller, W. L. (2010). Substrate-
specific modulation of CYP3A4 activity by genetic variants of cytochrome
P450 oxidoreductase. Pharmacogenet. Genomics 20, 611–618. doi: 10.1097/FPC.
0b013e32833e0cb5
Agrawal, V., Huang, N., and Miller, W. L. (2008). Pharmacogenetics of
P450 oxidoreductase: effect of sequence variants on activities of CYP1A2
and CYP2C19. Pharmacogenet. Genomics 18, 569–576. doi: 10.1097/FPC.
0b013e32830054ac
Aigrain, L., Pompon, D., Morera, S., and Truan, G. (2009). Structure of the open
conformation of a functional chimeric NADPH cytochrome P450 reductase.
EMBO Rep. 10, 742–747. doi: 10.1038/embor.2009.82
Arlt, W., Walker, E. A., Draper, N., Ivison, H. E., Ride, J. P., Hammer, F., et al.
(2004). Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase
and human androgen synthesis: analytical study. Lancet 363, 2128–2135.
doi: 10.1016/S0140-6736(04)16503-3
Augarten, A., Pariente, C., Gazit, E., Chayen, R., Goldfarb, H., and Sack, J.
(1992). Ambiguous genitalia due to partial activity of cytochromes P450c17 and
P450c21. J. Steroid Biochem. Mol. Biol. 41, 37–41. doi: 10.1016/0960-0760(92)
90222-5
Burkhard, F. Z., Parween, S., Udhane, S. S., Flück, C. E., and Pandey, A. V. (2017).
P450 Oxidoreductase deficiency: analysis of mutations and polymorphisms.
J. Steroid Biochem. Mol. Biol. 165(Pt A), 38–50. doi: 10.1016/j.jsbmb.2016.
04.003
Faeder, E. J., and Siegel, L. M. (1973). A rapid micromethod for determination of
FMN and FAD in mixtures. Anal. Biochem. 53, 332–336. doi: 10.1016/0003-
2697(73)90442-9
Flück, C. E., Mallet, D., Hofer, G., Samara-Boustani, D., Leger, J., Polak, M.,
et al. (2011). Deletion of P399_E401 in NADPH cytochrome P450
oxidoreductase results in partial mixed oxidase deficiency. Biochem.
Biophys. Res. Commun. 412, 572–577. doi: 10.1016/j.bbrc.2011.
08.001
Flück, C. E., Mullis, P. E., and Pandey, A. V. (2010). Reduction in hepatic
drug metabolizing CYP3A4 activities caused by P450 oxidoreductase
mutations identified in patients with disordered steroid metabolism.
Biochem. Biophys. Res. Commun. 401, 149–153. doi: 10.1016/j.bbrc.2010.
09.035
Frontiers in Pharmacology | www.frontiersin.org 9 August 2017 | Volume 8 | Article 580
fphar-08-00580 August 23, 2017 Time: 16:56 # 10
Udhane et al. Altered CYP19A1 by POR Variations
Flück, C. E., and Pandey, A. V. (2014). Steroidogenesis of the testis – new genes and
pathways. Ann. Endocrinol. (Paris) 75, 40–47. doi: 10.1016/j.ando.2014.03.002
Flück, C. E., and Pandey, A. V. (2017). Impact on CYP19A1 activity by mutations
in NADPH cytochrome P450 oxidoreductase. J. Steroid Biochem. Mol. Biol.
165(Pt A), 64–70. doi: 10.1016/j.jsbmb.2016.03.031
Flück, C. E., Tajima, T., Pandey, A. V., Arlt, W., Okuhara, K., Verge, C. F., et al.
(2004). Mutant P450 oxidoreductase causes disordered steroidogenesis with
and without Antley-Bixler syndrome. Nat. Genet. 36, 228–230. doi: 10.1038/
ng1300
Fukami, M., Hasegawa, T., Horikawa, R., Ohashi, T., Nishimura, G., Homma, K.,
et al. (2006). Cytochrome P450 oxidoreductase deficiency in three patients
initially regarded as having 21-hydroxylase deficiency and/or aromatase
deficiency: diagnostic value of urine steroid hormone analysis. Pediatr. Res. 59,
276–280. doi: 10.1203/01.pdr.0000195825.31504.28
Fukami, M., Horikawa, R., Nagai, T., Tanaka, T., Naiki, Y., Sato, N., et al.
(2005). Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler
syndrome with abnormal genitalia and/or impaired steroidogenesis: molecular
and clinical studies in 10 patients. J. Clin. Endocrinol. Metab. 90, 414–426.
doi: 10.1210/jc.2004-0810
Gomes, A. M., Winter, S., Klein, K., Turpeinen, M., Schaeffeler, E., Schwab, M.,
et al. (2009). Pharmacogenomics of human liver cytochrome P450
oxidoreductase: multifactorial analysis and impact on microsomal drug
oxidation. Pharmacogenomics 10, 579–599. doi: 10.2217/pgs.09.7
Gomes, L. G., Huang, N., Agrawal, V., Mendonca, B. B., Bachega, T. A., and
Miller, W. L. (2008). The common P450 oxidoreductase variant A503V is not
a modifier gene for 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 93,
2913–2916. doi: 10.1210/jc.2008-0304
Guengerich, F. P. (2005). Reduction of cytochrome b5 by NADPH-cytochrome
P450 reductase. Arch. Biochem. Biophys. 440, 204–211. doi: 10.1016/j.abb.2005.
06.019
Guengerich, F. P., Martin, M. V., Sohl, C. D., and Cheng, Q. (2009). Measurement
of cytochrome P450 and NADPH-cytochrome P450 reductase. Nat. Protoc. 4,
1245–1251. doi: 10.1038/nprot.2009.121
Homma, K., Hasegawa, T., Nagai, T., Adachi, M., Horikawa, R., Fujiwara, I.,
et al. (2006). Urine steroid hormone profile analysis in cytochrome
P450 oxidoreductase deficiency: implication for the backdoor pathway to
dihydrotestosterone. J. Clin. Endocrinol. Metab. 91, 2643–2649. doi: 10.1210/
jc.2005-2460
Huang, N., Agrawal, V., Giacomini, K. M., and Miller, W. L. (2008). Genetics of
P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities
and activities of 15 missense mutations. Proc. Natl. Acad. Sci. U.S.A. 105,
1733–1738. doi: 10.1073/pnas.0711621105
Huang, N., Pandey, A. V., Agrawal, V., Reardon, W., Lapunzina, P. D., Mowat, D.,
et al. (2005). Diversity and function of mutations in p450 oxidoreductase in
patients with Antley-Bixler syndrome and disordered steroidogenesis. Am. J.
Hum. Genet. 76, 729–749. doi: 10.1086/429417
Kagawa, N. (2011). Efficient expression of human aromatase (CYP19) in E. coli.
Methods Mol. Biol. 705, 109–122. doi: 10.1007/978-1-61737-967-3-7
Kagawa, N., Cao, Q., and Kusano, K. (2003). Expression of human aromatase
(CYP19) in Escherichia coli by N-terminal replacement and induction of cold
stress response. Steroids 68, 205–209. doi: 10.1016/S0039-128X(02)00168-X
Kurzban, G. P., and Strobel, H. W. (1986). Preparation and characterization
of FAD-dependent NADPH-cytochrome P-450 reductase. J. Biol. Chem. 261,
7824–7830.
Lephart, E. D., and Simpson, E. R. (1991). Assay of aromatase
activity. Methods Enzymol. 206, 477–483. doi: 10.1016/0076-6879(91)
06116-K
Lu, A. Y., Junk, K. W., and Coon, M. J. (1969). Resolution of the cytochrome P-450-
containing w-hydroxylation system of liver microsomes into three components.
J. Biol. Chem. 244, 3714–3721.
Marohnic, C. C., Panda, S. P., McCammon, K., Rueff, J., Masters, B. S.,
and Kranendonk, M. (2010). Human cytochrome P450 oxidoreductase
deficiency caused by the Y181D mutation: molecular consequences and
rescue of defect. Drug Metab. Dispos. 38, 332–340. doi: 10.1124/dmd.109.
030445
Matsubara, T., Baron, J., Peterson, L. L., and Peterson, J. A. (1976).
NADPH-cytochrome P450 reductase. Arch. Biochem. Biophys. 172, 463–469.
doi: 10.1016/0003-9861(76)90099-0
Michaelis, L., and Menten, M. L. (1913). Die Kinetik der Invertinwirkung. Biochem.
Z. 49, 333–369.
Miller, W. L., Huang, N., Flück, C. E., and Pandey, A. V. (2004). P450
oxidoreductase deficiency. Lancet 364, 1663. doi: 10.1016/S0140-6736(04)
17344-3
Nagao, M., Ishibashi, T., Okayasu, T., and Imai, Y. (1983). Possible involvement
of NADPH-cytochrome P450 reductase and cytochrome b5 on beta-
ketostearoyl-CoA reduction in microsomal fatty acid chain elongation
supported by NADPH. FEBS Lett. 155, 11–14. doi: 10.1016/0014-5793(83)
80198-7
Nicolo, C., Flück, C. E., Mullis, P. E., and Pandey, A. V. (2010). Restoration
of mutant cytochrome P450 reductase activity by external flavin. Mol. Cell.
Endocrinol. 321, 245–252. doi: 10.1016/j.mce.2010.02.024
Omura, T. (2006). Mitochondrial P450s. Chem. Biol. Interact. 163, 86–93.
doi: 10.1016/j.cbi.2006.06.008
Omura, T. (2010). Structural diversity of cytochrome P450 enzyme system.
J. Biochem. 147, 297–306. doi: 10.1093/jb/mvq001
Pandey, A. V. (2006). Biochemical analysis of mutations in P450 oxidoreductase.
Biochem. Soc. Trans. 34(Pt 6), 1186–1191. doi: 10.1042/BST0341186
Pandey, A. V., and Flück, C. E. (2013). NADPH P450 oxidoreductase:
structure, function, and pathology of diseases. Pharmacol. Ther. 138, 229–254.
doi: 10.1016/j.pharmthera.2013.01.010
Pandey, A. V., Fluck, C. E., Huang, N., Tajima, T., Fujieda, K., and Miller, W. L.
(2004). P450 oxidoreductase deficiency: a new disorder of steroidogenesis
affecting all microsomal P450 enzymes. Endocr. Res. 30, 881–888. doi: 10.1081/
ERC-200044134
Pandey, A. V., Flück, C. E., and Mullis, P. E. (2010). Altered heme catabolism by
heme oxygenase-1 caused by mutations in human NADPH cytochrome P450
reductase. Biochem. Biophys. Res. Commun. 400, 374–378. doi: 10.1016/j.bbrc.
2010.08.072
Pandey, A. V., Kempna, P., Hofer, G., Mullis, P. E., and Flück, C. E.
(2007). Modulation of human CYP19A1 activity by mutant NADPH P450
oxidoreductase. Mol. Endocrinol. 21, 2579–2595. doi: 10.1210/me.2007-0245
Pandey, A. V., and Sproll, P. (2014). Pharmacogenomics of human P450
oxidoreductase. Front. Pharmacol. 5:103. doi: 10.3389/fphar.2014.00103
Parween, S., Roucher-Boulez, F., Flück, C. E., Lienhardt-Roussie, A., Mallet, D.,
Morel, Y., et al. (2016). P450 oxidoreductase deficiency: loss of activity caused
by protein instability from a novel L374H mutation. J. Clin. Endocrinol. Metab.
101, 4789–4798. doi: 10.1210/jc.2016-1928
Przylepa, K. A., Paznekas, W., Zhang, M., Golabi, M., Bias, W., Bamshad,
M. J., et al. (1996). Fibroblast growth factor receptor 2 mutations in Beare-
Stevenson cutis gyrata syndrome. Nat. Genet. 13, 492–494. doi: 10.1038/
ng0896-492
Riddick, D. S., Ding, X., Wolf, C. R., Porter, T. D., Pandey, A. V., Zhang, Q. Y.,
et al. (2013). NADPH-cytochrome P450 oxidoreductase: roles in physiology,
pharmacology, and toxicology. Drug Metab. Dispos. 41, 12–23. doi: 10.1124/
dmd.112.048991
Schuster, I., and Bernhardt, R. (2007). Inhibition of cytochromes p450: existing
and new promising therapeutic targets. Drug Metab. Rev. 39, 481–499.
doi: 10.1080/03602530701498455
Shen, A. L., Porter, T. D., Wilson, T. E., and Kasper, C. B. (1989). Structural analysis
of the FMN binding domain of NADPH-cytochrome P-450 oxidoreductase by
site-directed mutagenesis. J. Biol. Chem. 264, 7584–7589.
Sim, S. C., Miller, W. L., Zhong, X. B., Arlt, W., Ogata, T., Ding, X., et al.
(2009). Nomenclature for alleles of the cytochrome P450 oxidoreductase
gene. Pharmacogenet. Genomics 19, 565–566. doi: 10.1097/FPC.0b013e32832
af5b7
Simpson, E. R., Mahendroo, M. S., Means, G. D., Kilgore, M. W., Hinshelwood,
M. M., Graham-Lorence, S., et al. (1994). Aromatase cytochrome P450, the
enzyme responsible for estrogen biosynthesis. Endocr. Rev. 15, 342–355.
Zalewski, A., Ma, N. S., Legeza, B., Renthal, N., Flück, C. E., and Pandey, A. V.
(2016). Vitamin D-dependent rickets type 1 caused by mutations in CYP27B1
affecting protein interactions with adrenodoxin. J. Clin. Endocrinol. Metab. 101,
3409–3418. doi: 10.1210/jc.2016-2124
Zanger, U. M., and Schwab, M. (2013). Cytochrome P450 enzymes in drug
metabolism: regulation of gene expression, enzyme activities, and impact of
genetic variation. Pharmacol. Ther. 138, 103–141. doi: 10.1016/j.pharmthera.
2012.12.007
Frontiers in Pharmacology | www.frontiersin.org 10 August 2017 | Volume 8 | Article 580
fphar-08-00580 August 23, 2017 Time: 16:56 # 11
Udhane et al. Altered CYP19A1 by POR Variations
Zhao, Q., Modi, S., Smith, G., Paine, M., McDonagh, P. D., Wolf, C. R., et al. (1999).
Crystal structure of the FMN-binding domain of human cytochrome P450
reductase at 1.93 A resolution. Protein Sci. 8, 298–306. doi: 10.1110/ps.8.2.298
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2017 Udhane, Parween, Kagawa and Pandey. This is an open-access
article distributed under the terms of the Creative Commons Attribution License
(CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Pharmacology | www.frontiersin.org 11 August 2017 | Volume 8 | Article 580
